Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. It may also stop the growth of tumor cells by blocking blood flow to
the tumor. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving
bortezomib together with docetaxel may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving bortezomib together with docetaxel
works in treating patients with recurrent or metastatic head and neck cancer.